Citable company snapshot
Edwards Lifesciences's latest SEC-sourced 2026-06-30 period shows $1.74B in revenue and $241.90M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 30, 2026 | $1.74B | $1.65B | +5.6% |
| Gross Profit | Jun 30, 2026 | $1.35B | $1.29B | +4.9% |
| Operating Income | Jun 30, 2026 | $513.20M | $477.60M | +7.5% |
| Net Income | Jun 30, 2026 | $241.90M | $380.70M | -36.5% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $651.90M | $43.80M | +1388.4% |
| Free Cash Flow (computed) | Jun 30, 2026 | $585.00M | $-21.10M | +2872.5% |
Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Aug 4, 2026; accession 0001099800-26-000043.
EW company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.